EXPLAINED: 2 | Vintage Vibes

CoreWeave's $9 Billion Bet Turns Crypto Miner Into AI Powerhouse

CoreWeave Inc (NASDAQ:CRWV) has announced an all-stock purchase of Core Scientific Inc (NASDAQ:CORZ) in a deal valued at about $20.40 per share, or roughly $9 billion, according to HC Wainwright.

Benzinga · Jul 8, 2025

Telix Pharmaceuticals Trial Enter Critical Stage, Analyst Predicts Big Gains

Telix Pharmaceuticals Ltd (NASDAQ:TLX) is the world's most "diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company," according to HC Wainwright.

Benzinga · Jul 3, 2025

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

MarketBeat · Jun 28, 2025

2 Penny Stocks That Wall Street Believes Can Soar Around 292% to 442%

Analysts believe these two penny stocks have outstanding long-term potential.

Barchart · Aug 28, 2024

Mizuho Analyst Remains Bullish On The EV Sector; Finds Rivian Better Positioned

Mizuho analyst Vijay Rakesh reiterated his Buy ratings on Rivian Automotive, Inc (NASDAQ:RIVN) and the $65 price target.  He saw RIVN as a pure play and a strong early mover in the EV market, focusing on the higher-growth SUV and light truck market and a robust commercial vehicle roadmap beginning with Amazon.Com, Inc. (NASDAQ:AMZN). Rivian is…

Benzinga · Oct 6, 2022

HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging

Ayala Pharmaceuticals Inc (NASDAQ:AYALA) reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday.  At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity.  HC Wainwright reiterated the Buy rating on the…

Benzinga · Jul 6, 2022

HC Wainwright Finds 'Synergies In Treatment' For This Bipolar-Focused Stock

HC Wainwright initiated coverage on NRx Pharmaceuticals Inc (NASDAQ:NRXP) with a Buying rating and a price target of $2. Earlier today, the FDA declined to issue an Emergency Use Authorization for NRx's Zyesami for a subgroup of patients who also received Gilead Sciences Inc's (NASDAQ:GILD) remdesivir in addition to Zyesami. The analyst is bullish on: Significant potential for NRX-101 for…

Benzinga · Jul 1, 2022

HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock

HC Wainwright has initiated Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22 (310% upside). The analysts see gastrointestinal stromal tumors (GISTs) treatment space reigniting with the entrance of a Theseus' pan-KIT inhibitor THE-630, with a high likelihood of 5L approval with earlier line potential.  The analysts believe THE-630 can…

Benzinga · Jul 1, 2022

Analysts Still Believe Verrica's Ycanth Is Approvable Despite FDA Response Letter

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) held a Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of Ycanth (VP-102) for molluscum contagiosum. HC Wainwright says VP-102 was approvable, and at the time of the Complete Response Letter (CRL), Verrica had already engaged a potential alternate solution supplier.  It reiterates…

Benzinga · Jun 29, 2022

Why Did HC Wainwright Downgrade Addex Therapeutics

Last week, Addex Therapeutics Ltd (NASDAQ:ADXN) terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow rate of patient recruitment.  Addex is suspending its financial guidance. Hence HC Wainwright downgraded its rating to Neutral from Buy without a price target, as dipraglurant…

Benzinga · Jun 23, 2022